热门出版物 - 学术资源搜索

h5 指数:95
h5 中位数:138

h5 指数是指在过去整整 5 年中所发表文章的 h 指数。h 指在 2018-2022 年间发表的 h 篇文章每篇至少都被引用过 h 次的最大值。隐藏

出版物的 h5 中位数，是指出版物的 h5 指数所涵盖的所有文章获得的引用次数的中位值。隐藏

#3 Hematology
#20 Oncology

标题/作者	引用次数	年份
European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia A Hochhaus, M Baccarani, RT Silver, C Schiffer, JF Apperley, F Cervantes, ... Leukemia 34 (4), 966-984	565	2020
Targeting FLT3 mutations in AML: review of current knowledge and evidence N Daver, RF Schlenk, NH Russell, MJ Levis Leukemia 33 (2), 299-312	478	2019
The MLL recombinome of acute leukemias in 2017 C Meyer, T Burmeister, D Gröger, G Tsaur, L Fechina, A Renneville, ... Leukemia 32 (2), 273-284	442	2018
Clinical use of lentiviral vectors MC Milone, U O’Doherty Leukemia 32 (7), 1529-1541	434	2018
Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma J Flores-Montero, L Sanoja-Flores, B Paiva, N Puig, O García-Sánchez, ... Leukemia 31 (10), 2094-2103	424	2017
Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity E Liu, Y Tong, G Dotti, H Shaim, B Savoldo, M Mukherjee, J Orange, ... Leukemia 32 (2), 520-531	389	2018
COVID-19 in persons with haematological cancers W He, L Chen, L Chen, G Yuan, Y Fang, W Chen, D Wu, B Liang, X Lu, ... Leukemia 34 (6), 1637-1645	368	2020
Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet T Barbui, A Tefferi, AM Vannucchi, F Passamonti, RT Silver, R Hoffman, ... Leukemia 32 (5), 1057-1069	360	2018
Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome JE Cortes, FH Heidel, A Hellmann, W Fiedler, BD Smith, T Robak, ... Leukemia 33 (2), 379-389	351	2019
Isocitrate dehydrogenase mutations in myeloid malignancies BC Medeiros, AT Fathi, CD DiNardo, DA Pollyea, SM Chan, R Swords Leukemia 31 (2), 272-281	295	2017
Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study JA Burger, PM Barr, T Robak, C Owen, P Ghia, A Tedeschi, O Bairey, ... Leukemia 34 (3), 787-798	276	2020
Acute myeloid leukemia transforms the bone marrow niche into a leukemia-permissive microenvironment through exosome secretion B Kumar, M Garcia, L Weng, X Jung, JL Murakami, X Hu, T McDonald, ... Leukemia 32 (3), 575-587	255	2018
Results of NOPHO ALL2008 treatment for patients aged 1–45 years with acute lymphoblastic leukemia N Toft, H Birgens, J Abrahamsson, L Griškevičius, H Hallböök, M Heyman, ... Leukemia 32 (3), 606-615	255	2018
A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis BA Walker, K Mavrommatis, CP Wardell, TC Ashby, M Bauer, F Davies, ... Leukemia 33 (1), 159-170	251	2019
Impact of corticosteroid therapy on outcomes of persons with SARS-CoV-2, SARS-CoV, or MERS-CoV infection: a systematic review and meta-analysis H Li, C Chen, F Hu, J Wang, Q Zhao, RP Gale, Y Liang Leukemia 34 (6), 1503-1511	245	2020
Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study A Hochhaus, T Masszi, FJ Giles, JP Radich, DM Ross, ... Leukemia 31 (7), 1525-1531	241	2017
Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy UH Gandhi, RF Cornell, A Lakshman, ZJ Gahvari, E McGehee, ... Leukemia 33 (9), 2266-2275	240	2019
Trends in overall survival and costs of multiple myeloma, 2000–2014 R Fonseca, S Abouzaid, M Bonafede, Q Cai, K Parikh, L Cosler, ... Leukemia 31 (9), 1915-1921	238	2017
Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond CS Chim, SK Kumar, RZ Orlowski, G Cook, PG Richardson, MA Gertz, ... Leukemia 32 (2), 252-262	237	2018
Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL JR Brown, P Hillmen, S O’Brien, JC Barrientos, NM Reddy, SE Coutre, ... Leukemia 32 (1), 83-91	217	2018

1 - 20

计算机程序会自动估算并确定日期和引用次数。